Burjeel Medical City offers advanced treatments and a multidisciplinary approach to provide the best care for patients with Peritoneal Carcinomatosis. Our Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are the gold standard treatments for this condition, and that is why Burjeel Medical City is a leading center for this specialized therapy.
What is Peritoneal Carcinomatosis?
Peritoneal Carcinomatosis refers to the spread of tumors that affect the peritoneal serosa and nearby structures in the abdomen. Peritoneal Carcinomatosis is commonly associated with malignancies originating from the gastrointestinal tract, ovaries, or primary peritoneal tumors. It can range from small implants near the primary tumor to large masses that occupy the entire abdomen and pelvis.
Can Peritoneal Carcinomatosis be Treated?
Over the last two decades, Peritoneal Carcinomatosis has been regarded as a locoregional disease and treated with curative intent. Accumulating evidence suggests that CRS+HIPEC offers a potentially curative treatment approach that can improve disease-free survival, reduce the risk of recurrence, and maintain a high quality of life for patients. Several well-conducted studies have shown that a significant percentage of patients treated with CRS+HIPEC survive beyond 5 years, with many resuming their daily activities.
Treatment of Peritoneal Carcinomatosis: Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
At Burjeel Medical City (BMC), we employ Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as the standard treatment for Peritoneal Carcinomatosis. This comprehensive approach involves radical surgery followed by the immediate administration of intraperitoneal chemotherapy, with or without hyperthermia, to eradicate microscopic tumor remnants after surgery.
Indications for CRS+HIPEC
Our esteemed Multidisciplinary Team (MDT) Oncology recommends CRS+HIPEC as a potential treatment option for Peritoneal Carcinomatosis arising from the following diseases:
- Appendiceal pseudomyxoma peritonei
- Malignant peritoneal mesothelioma
- Ovarian carcinoma
- Colorectal tumors
- Gastric cancer
- Peritoneal sarcomatosis
Patient Selection for CRS+HIPEC
Patient selection for CRS+HIPEC is crucial and should be conducted by an experienced multidisciplinary team in specialized centers like BMC. Not all patients with Peritoneal Carcinomatosis are suitable candidates for this complex procedure. Factors considered during the evaluation include:
- Approximately 10% of Peritoneal Carcinomatosis patients may be eligible for CRS+HIPEC with curative intent.
- Age is a consideration, but there is no specific age cut-off for contraindicating CRS+HIPEC.
- Absolute contraindications for CRS+HIPEC include severe cardiopulmonary or renal failure, Peritoneal Carcinomatosis of specific origins (mammary, biliary, pancreatic, or bronchopulmonary), urinary bladder infiltration/retraction, extra-abdominal or liver metastases, presence of another malignant tumor disease, complete bowel obstruction, and impossibility of proper follow-up.
Choose Burjeel Medical City for Superior Peritoneal Carcinomatosis Treatment
Burjeel Medical City stands as a premier destination for CRS+HIPEC treatment in the UAE, offering world-class multidisciplinary therapy for patients with Peritoneal Carcinomatosis. Our experienced team and state-of-the-art facilities ensure the best possible outcomes for eligible patients. Contact us today to learn more about our services and schedule a consultation.
